Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide cancer care without biopsy

NCT ID NCT07673861

Knowledge-focused Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovarian cancer. The test looks for genetic changes that may indicate resistance to current therapy or suggest alternative treatments. A panel of experts reviews the results to see if they can guide therapy choices, offer additional prognostic information, or eliminate the need for a tissue biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Marsden360 ctDNA test
What this could lead to
If successful, this approach could make cancer care more personalized by using a simple blood test to guide treatment decisions and reduce the need for invasive biopsies.
What could go wrong
This is an early-stage study with only 100 participants, so results may not apply to all patients. The test may not always provide useful information or change treatment plans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria All cohorts: * Age ≥18 years old * Ability to provide written informed consent * Presence of metastatic or unresectable disease * Being reviewed and treated through medical oncology service at Royal Marsden Hospital Cohort 1: Locally Advanced/Metastatic NSCLC * Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 2: Locally Advanced/Metastatic GIST * Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 3: Metastatic Colorectal Cancer • Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND * If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent * If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent Cohort 4: Locally Advanced/Metastatic BTC * Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency \[dMMR\]), AND * Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent Cohort 5: Advanced/Metastatic ovarian cancer * Diagnosis of advanced/metastatic high-grade ovarian cancer, AND * Known BRCA status, AND * Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent Exclusion Criteria All cohorts: * Medically unstable to commit to sampling required for the study * ECOG performance status ≥3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colorectal cancer colorectal neoplasm gastrointestinal stromal tumor non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer Colorectal cancer Gastrointestinal stromal tumor (GIST) Non-small cell lung cancer Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.